A population perspective on the use of external beam radiotherapy in Catalonia, Spain.


Journal

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 04 03 2020
accepted: 28 04 2020
pubmed: 20 5 2020
medline: 13 7 2021
entrez: 20 5 2020
Statut: ppublish

Résumé

To assess the use of external beam radiotherapy in Catalonia (Spain), overall and by health management area. We assessed radiotherapy treatments in a cohort of patients diagnosed with cancer from 2009 to 2011, using the population-based cancer registries in Girona and Tarragona. Participants had to have a minimum follow-up of 5 years from the time the cancer registry database was linked to the catalan health service database for financing radiation oncology. Outcomes included the proportion of patients receiving radiotherapy within 1 and 5 years of diagnosis. A log-binomial model was used to assess age-related trends in the use of radiotherapy by tumour site. Finally, we calculated the standardized utilization rate and 95% confidence intervals by health management area covered by the radiation oncology services, using indirect methods. At 1 and 5 years from diagnosis, 21.4 and 24.4% of patients, respectively, had received external beam radiotherapy. Patients aged 40-64 years had the most indications for the treatment, and there was a negative correlation between the patients' age and the use of radiotherapy for most tumour sites (exceptions were cervical, thyroid, and uterine cancers). There were no statistically significant differences in the use of radiotherapy according to th health management area. Population-based data show that external beam radiotherapy is underutilized in Catalonia. This situation requires a careful analysis to understand the causes, as well as an improvement of the available resources, oriented toward achieving realistic targets for the optimal use of external beam radiotherapy in our country.

Identifiants

pubmed: 32424700
doi: 10.1007/s12094-020-02355-1
pii: 10.1007/s12094-020-02355-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2222-2229

Subventions

Organisme : Instituto de Salud Carlos III
ID : PI15/00945
Organisme : Agència de Gestió d'Ajuts Universitaris i de Recerca
ID : 2017SGR00935

Auteurs

J Corral (J)

Cancer Plan, Department of Health, Generalitat de Catalunya, Barcelona, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.

J Solà (J)

Cancer Plan, Department of Health, Generalitat de Catalunya, Barcelona, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.

J Galceran (J)

Tarragona Cancer Registry, Foundation League for Research Into the Prevention of Cancer (FUNCA), Reus, Spain.
Pere Virgili Health Research Institute (IISPV), Reus, Spain.

R Marcos-Gragera (R)

Epidemiology Unit and Girona Cancer Registry, Cancer Plan, Department of Health, Generalitat de Catalunya, Catalan Institute of Oncology, Girona, Spain.
Descriptive Epidemiology, Genetics and Cancer Prevention Group, Biomedical Research Institute (IDIBGI), Girona, Spain.
University of Girona (UdG), Girona, Spain.
Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

M Carulla (M)

Tarragona Cancer Registry, Foundation League for Research Into the Prevention of Cancer (FUNCA), Reus, Spain.
Pere Virgili Health Research Institute (IISPV), Reus, Spain.

Á Izquierdo (Á)

Epidemiology Unit and Girona Cancer Registry, Cancer Plan, Department of Health, Generalitat de Catalunya, Catalan Institute of Oncology, Girona, Spain.
Descriptive Epidemiology, Genetics and Cancer Prevention Group, Biomedical Research Institute (IDIBGI), Girona, Spain.
Medical Oncology Department, Hospital Josep Trueta, Catalan Institute of Oncology of Girona, Girona, Spain.

L Vilardell (L)

Epidemiology Unit and Girona Cancer Registry, Cancer Plan, Department of Health, Generalitat de Catalunya, Catalan Institute of Oncology, Girona, Spain.
Descriptive Epidemiology, Genetics and Cancer Prevention Group, Biomedical Research Institute (IDIBGI), Girona, Spain.

L Llauradó (L)

Tarragona Cancer Registry, Foundation League for Research Into the Prevention of Cancer (FUNCA), Reus, Spain.

J A Espinàs (JA)

Cancer Plan, Department of Health, Generalitat de Catalunya, Barcelona, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.

J M Borras (JM)

Cancer Plan, Department of Health, Generalitat de Catalunya, Barcelona, Spain. jmborras@iconcologia.net.
Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. jmborras@iconcologia.net.
Department of Clinical Sciences, University of Barcelona, Barcelona, Spain. jmborras@iconcologia.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH